Articles tagged with Breast Cancer
University of Minnesota researchers have provided unprecedented images of cancer genome-mutating enzymes acting on DNA, offering vital clues into how these enzymes promote tumor evolution. The findings suggest ways to block enzyme activity in cancer, potentially making current anti-cancer therapies more effective.
A genetic biomarker, rs28714259, identifies women with breast cancer at increased risk for anthracycline-induced congestive heart failure. The marker is associated with low ventricular ejection fraction and may help oncologists provide more precise predictions of treatment risks.
A new UCL-led phase III clinical trial found that vascular-targeted photodynamic therapy (VTP) can effectively kill cancer cells while preserving healthy tissue. Around half of patients treated with VTP went into complete remission, compared to 13.5% in the control group.
A subgroup analysis of the MONALEESA-2 trial found that ribociclib improves progression-free survival in Asian patients with HR-positive advanced breast cancer. The treatment was well-tolerated and demonstrated efficacy regardless of geographic region or self-reported race.
A recent study by University of British Columbia researchers found that excessive reoperations in breast cancer surgeries result in significant costs to the Canadian healthcare system. The study concludes that with current reoperation rates being over double recommended targets, the additional cost is substantial.
Research by Dr. Josef Penninger found that RANKL inhibition can delay and prevent breast cancer development in mice with mutated BRCA1. The loss of RANK also impaired tumor progression, raising the possibility of a novel targeted approach for breast cancer prevention.
A study of over 5,500 women found that younger patients and those who had taken hormone replacement therapy were less likely to adhere to their medicine. The researchers identified several factors that contributed to non-adherence, including socioeconomic status and marital status, highlighting the need for targeted strategies to impro...
Researchers developed RNA nanoparticles that selectively bind to HER2-overexpressing breast tumors, eliminating MED1 expression and sensitizing them to tamoxifen treatment. The nanoparticles also reduced cancer stem cell content, a promising strategy for treating advanced metastatic breast cancer.
A study found a 64% spike in genetic tests for breast cancer following Angelina Jolie's op-ed piece, but no uptick in mastectomy rates. The tests did not lead to additional breast cancer diagnoses, suggesting overtesting among low-risk groups.
US women saw a sharp increase in breast cancer gene testing after Angelina Jolie's article, with daily rates rising 64% immediately. However, there was no change in overall mastectomy rates, suggesting that celebrity endorsements may not effectively target high-risk groups.
A UT Dallas biologist and his team discovered that NQO1 and HIF-1a, two enzymes previously linked to cancer cell survival, actually work in tandem to promote tumor growth. The researchers found that NQO1 binds to HIF-1a, stabilizing it and preventing its degradation.
Researchers have identified a new subtype of triple negative breast cancer that may be more responsive to treatment, including immunotherapies. The study found that patients with BRCA deficient tumors had better survival rates and higher burdens of mutations that could be targeted by the immune system.
The new guidelines recommend forego routine axillary lymph node dissection in most women with no evidence of cancer on sentinel node biopsy. This approach can reduce the risk of painful and costly side effects such as lymphedema, infections, and reduced range of motion.
A new study found that socially isolated breast cancer survivors had a 40% higher risk of recurrence, a 60% higher risk of dying from breast cancer, and a 70% higher risk of dying from any cause. Women with larger social networks experienced better outcomes.
Researchers discovered an antibody that normalizes tumor blood vessels, reducing volume and improving anti-cancer drug delivery. The antibody, ABTAA, restores vascular integrity in breast, lung, and brain tumors, leading to better oxygen supply and reduced metastasis.
A large Kaiser Permanente study found that socially integrated women had lower breast cancer death rates and disease recurrence compared to socially isolated women. The study suggests that specific types of social ties, such as friendships and family members, are beneficial for different sociodemographic groups.
A new study at SABCS finds EndoPredict, a second-generation test, superior to Oncotype Dx in predicting breast cancer recurrence. The test accurately identified patients with low risk of recurrence, allowing them to forgo chemotherapy.
A new Penn study sheds light on racial disparities in cancer-causing genetic mutations, finding differences in mutation patterns between African American and Caucasian women. The research suggests biological differences and potentially different genetic factors may be at play, guiding targeted care for at-risk patients.
A study published by University of Texas MD Anderson Cancer Center found that older women with breast cancer who underwent less radiation therapy reported improved cosmetic satisfaction. However, reduced radiation was also associated with a slightly increased risk of disease recurrence. The researchers suggest that there may be an opti...
A new study by SWOG found that duloxetine can significantly reduce joint pain in postmenopausal women with early stage breast cancer. The randomized trial tested the effectiveness of duloxetine against aromatase inhibitors, a common treatment for breast cancer, and showed rapid relief from pain.
A recent study published in Nature Reviews Cancer suggests that progesterone could be a game-changer in treating recurring breast cancers. The hormone, when used in combination with current treatments, may reprogram estrogen action in the breast to improve cancer outcomes. Two new clinical trials are underway to test this approach.
Women taking tamoxifen for breast cancer prevention experienced nausea and vomiting, which led them to discontinue the medication. A new analysis suggests that these symptoms were sometimes mistaken for tamoxifen side effects, highlighting the importance of accurate information on preventive therapies.
A pilot study at MD Anderson Cancer Center found that image-guided biopsies accurately predicted residual disease in breast cancer patients after chemotherapy and/or targeted therapy. The study suggests that certain patients may be able to avoid surgery, paving the way for personalized treatment.
Global breast cancer mortality rates declined between 1987-2013, with 39 countries showing a decrease, including the US and most developed European nations. However, South Korea experienced an 83% increase, while Latin America saw scattered increases in mortality, except for Argentina and Chile.
A new study reveals that many breast cancer survivors experience unmet needs for symptom management, leading to increased levels of anxiety and depression. Researchers are calling on healthcare providers to incorporate symptom management into routine follow-up care.
Researchers identified two drug combinations that could improve survival rates for breast cancer patients, including anti-inflammatory and lipid modifiers. The study analyzed data from nearly 10,000 women with breast cancer and found three pairs of drug interactions associated with better outcomes.
A study by researchers at UNC Lineberger Comprehensive Cancer Center identified biomarkers that predict how patients with HER2-positive breast cancer will respond to targeted treatment trastuzumab and chemotherapy. The biomarkers are based on gene signatures, genetic mutations, and immune responses.
A large multicenter cohort study found that radiation therapy increased complications and impaired patient-reported satisfaction with reconstructed breasts in breast cancer patients who received implant reconstruction. However, no worsening of outcomes was observed in those who received autologous reconstruction. The study suggests tha...
A team of scientists tracked the genetics of disseminated tumour cells in breast cancer patients, finding they are genetically similar to the original tumour. This knowledge could help clinicians choose the most effective therapy, potentially leading to better outcomes and a more accurate prognosis.
A new study finds that women who have implant reconstruction following radiation therapy had more complications from the surgery and were less satisfied with the result. Autologous reconstruction showed similar results, regardless of radiation treatment. The study suggests alternative approaches for breast cancer patients
A researcher at UH Seidman Cancer Center is presenting a phase II clinical trial testing the effectiveness of combining chemotherapy with an immunotherapeutic agent, pembrolizumab, for patients with metastatic triple-negative breast cancer. The trial aims to improve survival rates and reduce disease recurrence.
Researchers at UNC Lineberger Comprehensive Cancer Center developed a model that can predict which triple negative breast cancer patients will respond to chemotherapy. The model was moderately successful, accurately predicting response in 68% of cases with pathologic complete response.
A study found that women aged 65 years or older with metastatic breast cancer are more likely to have cancer-linked genetic alterations and receive targeted therapy than younger patients. Researchers emphasized the need to better understand and characterize genetic abnormalities in this age group to improve treatment options.
Rates of breast cancer brain metastasis have not substantially declined despite improved targeted treatments for HER2-positive metastatic breast cancer. Researchers found that the risk of death from brain metastasis is more than twice that of patients with metastasis to other areas of the body.
Researchers at the University of Pittsburgh Cancer Institute have discovered molecular changes in primary tumors of breast cancer patients who developed brain metastases. The findings suggest that targeted therapies should be tailored not only for the original breast cancer but also for the brain tumors.
Patients with large breast tumors and no axillary lymph node signs before chemotherapy showed low risk of recurrence with SLNB. Follow-up data revealed high disease-free survival rates comparable to ALND, suggesting SLNB as a safe alternative.
Researchers at Mayo Clinic found that inherited pathogenic variants in genes BARD1 and RAD51D increase a woman's likelihood of developing breast cancer. The study also confirmed the involvement of other genes such as ATM, CHEK2 and PALB2 in breast cancer risk.
A new study found that cancer cases are growing at an alarming rate in less developed countries, with a 50% increase between 2005 and 2015. The global burden of disease is heaviest for countries with high development levels, but the most rapid escalation can be seen in low-income nations where health services are often lacking.
Research papers in PLOS Medicine discuss progress in cancer genomics, including whole-genome sequencing and gene expression changes. Studies on breast cancer and brain tumors provide insights into tumor evolution and metastasis, potentially leading to new treatments and prognosis estimation.
A new class of NIR-absorbing biodegradable organic nanoparticles has been developed for the targeting and treatment of deep-tissue tumors. These molecules can be triggered by low-power lamp light, allowing for precise tumor-targeting therapy with minimal side effects.
Researchers at the Weizmann Institute of Science have identified a promising new combination therapy for triple negative breast cancer, which inhibits tumor growth and survival while preventing drug resistance. The therapy targets EGFR and PYK2 molecules, leading to a more potent therapeutic effect than inhibiting either molecule alone.
The study estimates 17.5 million cancer cases and 8.7 million cancer-related deaths worldwide in 2015, with prostate cancer being the most common in men and breast cancer in women. The report also highlights an increase in cancer incidence due to aging and demographic changes.
Renowned researchers Fergus Couch and Max Wicha are being honored by AACR for their significant work in breast cancer etiology, detection, diagnosis, treatment, or prevention. Their research has led to the identification of inherited genes and mutations that predispose to breast cancer.
Researchers found that blocking tumor interferon pathway with a JAK inhibitor improves checkpoint inhibitor drugs and bypasses the need for combinations, which often come with serious side effects. The study suggests a new approach to addressing cancer immunotherapies' limitations.
Research from Oregon State University reveals numerous gaps in survivorship care for Latinas, including unmet needs for information, symptom management, and coordination among specialists. The study highlights the importance of understanding cultural context and developing tailored support systems to address these gaps.
A phase I trial of LY3039478 showed the drug's ability to inhibit Notch signalling pathway in patients with various advanced cancers. The treatment resulted in tumour shrinkage and disease stabilisation, particularly in rare cancers like adenoid cystic carcinoma.
A proposed biosimilar drug has shown equivalent results to trastuzumab in treating metastatic breast cancer. The study's findings suggest that a biosimilar treatment option could increase global access to biologic cancer therapies, particularly for women in non-high-income countries.
A new optical fiber probe can distinguish between cancer and normal tissues in real-time, allowing for more precise removal of cancerous tissue during surgery. This technology has the potential to reduce the need for additional surgeries to remove leftover cancer.
Researchers at the University of Adelaide have developed an optical fiber probe that can distinguish breast cancer tissue from normal tissue. This technology has the potential to reduce unnecessary follow-up surgery for 15-20% of patients.
Researchers at Rice University have discovered that a diabetes drug can halt the production of glycoproteins that make up the protective mucus lining cells, allowing immune cells to target tumors. The study suggests that reducing mucin levels may be enough to breach the tumor's protective shield and allow for cancer cell destruction.
A phase I clinical trial has shown that the experimental drug TAS-114 can increase the effectiveness of chemotherapy while reducing side effects. The drug, combined with S-1, resulted in tumor shrinkage and stable disease progression in patients with various cancers, including non-small cell lung cancer, pancreatic cancer, and breast c...
A landmark clinical trial conducted by researchers at the University of Alberta found that beta blockers and ACE inhibitors effectively prevent a drop in heart function from cancer treatment. The study showed improved safety for breast cancer patients undergoing chemotherapy, with potential benefits to survival rates.
Researchers at Courage Kenny Rehabilitation Institute present studies on improving walking speed in stroke patients and managing cancer-related cognitive dysfunction, also known as chemobrain. Occupational therapy was found to improve everyday functioning and manage issues like mood, stress, and fatigue in cancer survivors.
Researchers at Thomas Jefferson University discovered that a protein called TIGAR promotes the growth of breast cancer cells by altering cell metabolism, which could be targeted with existing drugs like metformin and doxycycline. These therapies have already passed safety testing in humans and may help reduce tumor growth.
A large study analyzed over 5.6 million screening mammograms and found a gradual upward trend in cancer detection rates and positive predictive values with increasing age, but no clear evidence for age-based mammography cessation. The findings support guidelines encouraging individual patient decisions based on health status.
A study published by The Menopause Society confirms electro-acupuncture's effectiveness in reducing hot flash severity and improving sleep quality in breast cancer survivors. Electro-acupuncture has been shown to affect neurotransmitters associated with sleep, such as serotonin and melatonin.
PharmaMar is conducting a Phase I study to determine the recommended dose of PM1183 in Japanese patients, with secondary objectives including safety profile and antitumor activity evaluation. The study focuses on patients born in Japan or with Japanese ancestry affected by solid tumors.
Researchers discovered that low-dose chemotherapy regimens can prevent the secretion of proteins by fibroblast cells surrounding tumors, reducing the likelihood of tumor recurrence. Mice with breast or pancreatic cancer treated with these regimens survived longer than those receiving high-dose chemotherapy.
A new study found that most women in Virginia are unaware of the increased cancer risk associated with dense breasts. Only 1 in 8 women knew their breast density was a risk factor for breast cancer.
A recent study found that metformin treatment inhibits abnormal mitochondrial metabolism and activates anti-proliferation signaling in individuals with Li-Fraumeni syndrome. This inhibition leads to lower rates of tumor formation and increased survival time, suggesting metformin as a potential strategy for cancer prevention.